Document:

Supply Agreement

 Exhibit 10.24 
 SUPPLY AGREEMENT 
 THIS AGREEMENT, is made and entered into on and as of 23 July, 2001 by and
between INTERCHEM CORPORATION, a corporation of the State of New Jersey, having offices at 120 Route 17 North, Paramus, New Jersey 07852 (INTERCHEM) and POLI INDUSTRIA CHIMICA, SPA, a corporation of the country Italy, having offices at Via Volturno
48-20089, Quinto De Stampi, Rozzano, Milano, Italy (POLI), and LAYTON BIOSCIENCE INC., a corporation of the State of Delaware, having offices at 709 E. Evelyn Ave, Sunnyvale, CA. 94086 (LAYTON BIOSCIENCE). 
 WHEREAS POLI INDUSTRIA CHIMICA is in the business of producing bulk pharmaceuticals, and in particular expert in producing MECAMYLAMINE HYDROCHLORIDE and
its ISOMERS; 
 WHEREAS INTERCHEM is the exclusive United States agent for POLI INDUSTRIA CHIMICA for the sales of MECAMYLAMINE HYDROCHLORIDE
(PRODUCT) and ISOMERS (ISOMERS); 
 WHEREAS LAYTON BIOSCIENCE INC. wishes to secure a predictable and reliable source of bulk MECAMYLAMINE
HYDROCHLORIDE and ISOMERS; 
 WHEREAS POLI INDUSTRIA CHIMICA desires to provide bulk pharmaceutical PRODUCT and ISOMERS worldwide;

 WHEREAS POLI, INTERCHEM and LAYTON BIOSCIENCE desire to cooperate to achieve these objectives; and 
  

 - 1 - 

 NOW, THEREFORE, in consideration of the promises, covenants and representations of the PARTIES set forth
herein, and other good and sufficient consideration receipt of which is hereby acknowledged, LAYTON BIOSCIENCE, POLI, and INTERCHEM agree as follows: 
  

	 	1.	DEFINITIONS 

 PARTIES shall mean INTERCHEM
CORPORATION, POLI INDUSTRIA CHIMICA and LAYTON BIOSCIENCE INC., collectively. 
 LAYTON BIOSCIENCE shall mean LAYTON BIOSCIENCE INC., the
signatory to this Agreement, and all affiliates and successors of LAYTON BIOSCIENCE INC. 
 POLI shall mean POLI INDUSTRIA CHIMICA and its affiliates, the
signatory to this agreement, and all successors in interest. 
 INTERCHEM shall mean INTERCHEM CORPORATION and its affiliates, the signatory
to this Agreement, and all successors in interest. 
 PRODUCT shall mean the pharmaceutical PRODUCT identified as MECAMYLAMINE HYDROCHLORIDE.

  

 - 2 - 

 ISOMERS shall mean ISOMERS of MECAMYLAMINE that are patented by and the exclusive property of LAYTON
BIOSCIENCE. 
 AFFILIATE shall mean and include any individual, corporation, business association, or entity that controls, is controlled by,
or is under common control with the specified PARTY. For purposes of this definition, control shall mean direct or indirect beneficial ownership of more than fifty percent (50%) of the voting stock or other ownership or more than fifty percent
(50%) or more interest in the income of, such entity. Notwithstanding the foregoing, for purposes of this Agreement, INTERCHEM CORPORATION shall be deemed an affiliate of POLI INDUSTRIA CHIMICA. 
  

	 	2.	REQUIREMENTS CONTRACT 

 LAYTON BIOSCIENCE agrees to purchase its
requirements for the PRODUCT and ISOMERS exclusively from POLI through INTERCHEM. POLI and INTERCHEM agree to supply the PRODUCT to LAYTON BIOSCIENCE for its exclusive use in marketing pharmaceutical products that are indicated for hypertension,
neurological disorders, or psychiatric disorders, and to supply the PRODUCT to LAYTON BIOSCIENCE for its non-exclusive use in marketing pharmaceutical products indicated for any and all other indications. POLI and INTERCHEM agree to supply the
ISOMERS to LAYTON BIOSCIENCE for its exclusive use in marketing pharmaceutical products indicated for any and all indications. LAYTON BIOSCIENCE acknowledges that POLI and INTERCHEM are cooperating with another company for the use of the PRODUCT to
be combined with another active ingredient in a pharmaceutical product for the indication of smoking cessation, and that this grant of exclusivity in no way impairs the rights of POLI and INTERCHEM to continue such cooperation and to sell the
PRODUCT for use in combination with another active ingredient in a pharmaceutical product for the indication of smoking cessation. POLI and INTERCHEM therefore reserve the right to contract with third parties in order to combine PRODUCT with another
active ingredient and market the resulting pharmaceutical product for the indication of smoking cessation. 
  

 - 3 - 

 INTERCHEM agrees to supply and fill all orders from LAYTON BIOSCIENCE with PRODUCT and ISOMERS from
PRODUCT and ISOMERS manufactured by POLI upon order from LAYTON BIOSCIENCE except as provided herein or otherwise as agreed to in writing between LAYTON BIOSCIENCE and either of the other two PARTIES. Pursuant to the provisions of this Agreement,
POLI agrees to manufacture a sufficient quantity of the PRODUCT and ISOMERS to meet LAYTON BIOSCIENCE’s requirements for the same. 
  

	 	a.	Volume 

 To assist INTERCHEM and POLI in meeting
their obligations under this contract, LAYTON BIOSCIENCE will provide an annual forecast of its needs for the PRODUCT to INTERCHEM which forecast will be updated at least semi-annually. LAYTON BIOSCIENCE will purchase over the life of this Agreement
the minimum total volume of PRODUCT specified in Exhibit A. In addition, each year LAYTON BIOSCIENCE will purchase the minimum yearly volume of PRODUCT specified in Exhibit A. 
 Upon initiation of scale-up of batches for LAYTON BIOSCIENCE ISOMERS, LAYTON BIOSCIENCE will enter good faith negotiations with POLI and INTERCHEM to
determine minimum total volume requirements for such ISOMERS for the period of time remaining in the term of this Agreement. 
  

 - 4 - 

	 	b.	Orders 

 LAYTON BIOSCIENCE shall place written orders for the
PRODUCT and to the extent applicable, ISOMERS with INTERCHEM at least twelve (12) weeks in advance of the earliest delivery date required hereunder. Each order shall specify the delivery dates and quantity of the PRODUCT and/or ISOMERS ordered.
INTERCHEM shall promptly convey to POLI the quantity of PRODUCT and/or ISOMERS and delivery dates specified in the LAYTON BIOSCIENCE orders. POLI agrees to manufacture and ship to Siegfried CMS Ltd in Zofingen, Switzerland sufficient PRODUCT and/or
ISOMERS in a timely fashion so as to comply with LAYTON BIOSCIENCE’s orders. POLI shall ship PRODUCT and/or ISOMERS in accordance with such orders (provided such orders are within +/- 10% of LAYTON BIOSCIENCE’s forecast for any PRODUCT or
ISOMERS over the twelve (12) month period preceding the order) to Siegfried CMS Ltd F.O.B. in Zofingen, Switzerland. Title and risk of loss shall be POLI and INTERCHEM’s responsibility until delivered to LAYTON BIOSCIENCE or its agent
Siegfried CMS Ltd. in Zofingen, Switzerland. POLI or INTERCHEM may decline to accept orders for any of the PRODUCT or ISOMERS if either POLI or INTERCHEM has received the opinion of patent counsel that the production or sale of the PRODUCT or
ISOMERS would infringe on the patent rights of others in either the United States or the country in which POLI’s manufacturing facility is located. Pursuant to the requirements of Paragraph 3.d. of this Agreement, POLI or INTERCHEM will
promptly notify LAYTON BIOSCIENCE in such a circumstance, and provide LAYTON BIOSCIENCE with a reasonable opportunity to resolve such an issue. 
  

 - 5 - 

 Within thirty (30) days from the date of this Agreement, and at any other time during this
Agreement, POLI will advise if there are any existing patents in the country where POLI’s manufacturing facility is located which would preclude POLI from providing the PRODUCT or ISOMERS to LAYTON BIOSCIENCE and advise as to the first date
when POLI may lawfully supply the PRODUCT or ISOMERS. 
  

	 	c.	Modification of Orders 

 Orders may be modified only
upon six (6) weeks written notice to INTERCHEM. LAYTON BIOSCIENCE agrees to accept and pay for all PRODUCT and ISOMERS scheduled for delivery less than six (6) weeks prior to INTERCHEM’s receipt of such written notice on the terms and
conditions previously agreed to. INTERCHEM shall promptly notify POLI of any such modifications. ill no event may the volume of PRODUCT purchased in any calendar year be less than the yearly minimum specified in Exhibit A. 
  

	 	d.	Acceptance and Rejection 

 If LAYTON BIOSCIENCE
determines that any PRODUCT and/or ISOMERS is defective in material or workmanship, not in conformance with the specifications in Exhibit B or current Good Manufacturing Practices (cGMP) as determined by the United States Food and Drug
Administration (FDA), is adulterated or misbranded, or is otherwise not in conformity with this Agreement (Defective Product), then LAYTON BIOSCIENCE, in addition to any other rights it may have under this Agreement, may reject 

  

 - 6 - 

 
and return any such PRODUCT and/or ISOMERS to POLI and INTERCHEM. At the time of such rejection, LAYTON BIOSCIENCE shall provide INTERCHEM with a written
notice describing in detail the circumstances surrounding the rejection and LAYTON BIOSCIENCE’s reasons therefor. If LAYTON BIOSCIENCE rejects any PRODUCT and/or ISOMERS it will, at POLI and INTERCHEM’s option, either return them to POLI
or INTERCHEM, destroy or dispose of them in the least expensive and most environmentally sound manner, or take other actions as POLI and INTERCHEM may request, within reason. In any event, POLI and INTERCHEM shall be responsible for all costs of any
such return, destruction, disposal, or any other action. 
 LAYTON BIOSCIENCE or its agent shall promptly inspect each shipment of the PRODUCT and/or ISOMERS
and notify INTERCHEM of any deficiencies. It shall be the responsibility of INTERCHEM and POLI to promptly remedy any such deficiency. LAYTON BIOSCIENCE will make available samples of any allegedly defective PRODUCT and ISOMERS and, if requested,
return the same to INTERCHEM at INTERCHEM’s expense by the means specified by INTERCHEM. LAYTON BIOSCIENCE shall be deemed to have accepted a PRODUCT and/or ISOMERS shipment if written notice of any alleged deficiency is not received within
sixty (60) days from delivery to LAYTON BIOSCIENCE or its agent in Zofingen, Switzerland. 
 In the event LAYTON BIOSCIENCE receives
Defective Product from POLI or INTERCHEM, LAYTON BIOSCIENCE may avail itself, but is not limited to, the following remedies: (i) the replacement by POLI and INTERCHEM of rejected PRODUCT and/or ISOMERS that have either been returned or
destroyed with PRODUCT and ISOMERS that are not Defective Product; or (ii) a full refund of any amount paid hereunder by LAYTON BIOSCIENCE for such Defective Product. 
  

 - 7 - 

 If POLI and INTERCHEM replace such Defective Product with PRODUCT and ISOMERS that are not Defective Product within
thirty (30) days from their rejection, there will be no alteration of the minimum total volume of PRODUCT requirement for the life of this Agreement as specified in Exhibit A. If after receiving allegedly defective PRODUCT INTERCHEM/POLI
disagree with LAYTON BIOSCIENCE as to the existence of a defect, then INTERCHEM/POLI shall have the right to investigate the nature and existence of the defect in a commercially reasonable time. If after this time frame a disagreement between the
parties continues to exist then INTERCHEM/POLI will submit the samples to a mutually acceptable independent testing laboratory to test for the alleged defect. Results from the testing laboratory will be binding on both INTERCHEM/POLI, and LAYTON
BIOSCIENCE, and the costs for the independent testing will be borne by the Party against whom the laboratory decides. 
 The minimum total volume of PRODUCT
required under this Agreement as specified in Exhibit A will be reduced if and only if LAYTON BIOSCIENCE is forced, for a legitimate reason, to go to a third-party manufacturer for its PRODUCT or ISOMER needs. A legitimate reason includes four
circumstances: 1) if POLI and INTERCHEM are unable to supply PRODUCT or ISOMERS for any reason; 2) if POLI and INTERCHEM are unwilling to produce the PRODUCT or ISOMERS for any reason; 3) if POLI and INTERCHEM consistently fail to meet regulatory
specifications, including but not limited to U.S. Food and Drug Administration Current Good Manufacturing Practices, and any specifications listed under the terms of this agreement as specified at Exhibit B; or 

  

 - 8 - 

 
4) termination or expiration of this Agreement. LAYTON BIOSCIENCE will determine when and if POLI and INTERCHEM have consistently failed to meet regulatory
and product specifications. If a disagreement arises as to the existence of a consistent failure to meet regulatory specifications, related U.S. Food and Drug Administration action (including but not limited to issuance of Warning Letters or Form
483s) will serve as prima facie evidence thereof. In the absence of U.S. Food and Drug Administration action, the parties will submit the issue to a mutually acceptable third party arbitrator, whose decision will be final in accordance with
Paragraph 26 of this Agreement. The costs of the arbitration will be borne by the party against whom the arbitrator decides. 
  

	 	e.	Term 

 The term of the Agreement is five
(5) years from the date of Food and Drug Administration approval of Product or the effective date of this Agreement, whichever is later. It shall be thereafter automatically extended by a term of one (2) years except any PARTY may provide
written notice at least twelve (12) months prior to the expiration of any term that it does not wish the Agreement to be renewed for an additional one (2) year period. 
  

	 	3.	PATENTS AND PATENT INFRINGEMENT 

  

	 	a.	Validity of PARTIES Patents 

 INTERCHEM and POLI,
both independently and collectively, hereby represent and warrant that pursuant to its manufacturing and supply of PRODUCT and ISOMERS that to the best of their knowledge and belief the Patents they will utilize in the furtherance of the
manufacturing and supply of PRODUCT and ISOMERS have not been declared invalid or unenforceable, they have good title to such Patents and they are not aware of any application pending in relation to the same that in any way affects these Patents,
has not encumbered these Patents or taken any action whereby their title may be impugned or encumbered, or knowledge that these Patents infringe the claims of any third-party patent or other third-party property rights. 
  

 - 9 - 

 LAYTON BIOSCIENCE hereby represents and warrants that pursuant to its use of PRODUCT and ISOMERS, as
described at Paragraph 2 of this Agreement, that to the best of its knowledge and belief the Patents it will utilize in the furtherance of the use of PRODUCT and ISOMERS have not been declared invalid or unenforceable, it has good title to such
Patents and it is not aware of any application pending in relation to the same that in any way affects these Patents, has not charged or encumbered these Patents or taken any action whereby their title may be impugned or encumbered, or knowledge
that these Patents infringe the claims of any third-party patent or other third-party property rights. 
  

	 	b.	Patent and Know-How Rights Gained During Agreement 

 The PARTIES recognize that in the course of work under this Agreement, a PARTY may independently make or otherwise acquire rights to inventions (including without limitation, processes, methods, and improvements to the manufacturing
materials, equipment, procedure, or LAYTON BIOSCIENCE patents or other technology during the term of this Agreement) or know-how useful in the manufacture of PRODUCT or ISOMERS. In such event, the PARTY independently making or acquiring the
invention or know-how shall be the sole owner of that invention or know-how. 
  

 - 10 - 

 With respect to any such inventions or know-how for which POLI or INTERCHEM are the sole owner, POLI
and/or INTERCHEM will grant to LAYTON BIOSCIENCE or any acquiring entity of LAYTON BIOSCIENCE a non-exclusive, royalty-free license, with a right to sublicense, any know-how and patents or patent applications for such inventions under four
circumstances: 1) if POLI and INTERCHEM are unable to produce the PRODUCT or ISOMERS for any reason; 2) if POLI and INTERCHEM are unwilling to produce the PRODUCT or ISOMERS for any reason; 3) if POLI and INTERCHEM consistently fail to meet
regulatory and product specifications, including but not limited to U.S. Food and Drug Administration Current Good Manufacturing Practices, and any specifications listed under the terms of this agreement at Exhibit B; or 4) termination or expiration
of this Agreement. LAYTON BIOSCIENCE will determine in its sole discretion when and if POLI and INTERCHEM have consistently failed to meet regulatory and product specifications. If a disagreement arises as to the existence of a consistent failure to
meet regulatory specifications, related U.S. Food and Drug Administration action (including but not limited to issuance of Warning Letters or Form 483s) will serve as prima facie evidence thereof. In the absence of U.S. Food and Drug Administration
action, the parties will submit the issue to a mutually acceptable third party arbitrator, whose decision will be final in accordance with Paragraph 26 of this Agreement. The costs of the arbitration will be borne by the party against whom the
arbitrator decides. 
 To the extent that LAYTON BIOSCIENCE or any acquiring entity of LAYTON BIOSCIENCE sublicenses any POLI or INTERCHEM
inventions or know-how under these provisions, the licensees of such sublicenses are limited to entities manufacturing pharmaceutical products on behalf of LAYTON BIOSCIENCE or any acquiring entity of LAYTON BIOSCIENCE, and any such sublicenses must
state that the use of the POLI or INTERCHEM inventions or know-how are limited to manufacturing pharmaceutical products for the direct benefit of LAYTON BIOSCIENCE or any acquiring entity of LAYTON BIOSCIENCE. 
  

 - 11 - 

 With respect to any inventions that are jointly made by the PARTIES (i.e., inventions in which one or more
inventors from each PARTY have made an inventive contribution as determined by the laws of inventorship), including any inventions made by a PARTY’s employee or third-party contractor obliged to assign such invention to a PARTY, concerning
PRODUCT or ISOMERS or processes or methods relating to PRODUCT or ISOMERS, the PARTIES shall own such inventions (and any patent applications filed on such inventions and any patents issued on such inventions) jointly as co-owners of equal,
undivided shares without right of accounting for any act carried out in accordance with the invention, and agree to cooperate and assist one another in filing any patent applications and undertaking all other reasonable and appropriate protection
for such patentable joint inventions, including provision of powers of attorney for this purpose. 
 If any proceedings in bankruptcy or in
reorganization, or for the appointment of a receiver or trustee for all or a substantial portion for the assets of any PARTY to this Agreement, or any other like proceedings, under any law for the relief of debtors shall be instituted by or against
any PARTY hereto and are not dismissed within ninety (90) days, any patent or know-how rights gained during this Agreement shall pass to the successors in interest to the PARTIES. 
  

 - 12 - 

	 	c.	Prosecution of Joint Patents 

 LAYTON BIOSCIENCE shall have the
first right, but no obligation, to undertake joint patent filings and prosecution in one or more countries respecting jointly held inventions, subject to reimbursement from POLI and INTERCHEM for one-half of any reasonable out-of-pocket expenses
LAYTON BIOSCIENCE incurs in such filing and prosecution. In the event LAYTON BIOSCIENCE fails to undertake the filing of such a patent application within ninety (90) days of a notice by LAYTON BIOSCIENCE to POLI or INTERCHEM that it believes
the filing of such an application is appropriate, POLI and INTERCHEM may undertake such a filing at their own expense, in which event any subsequently issued patent application shall be owned solely by POLI or INTERCHEM. A PARTY may not assign its
rights to any jointly owned invention, application or subsequently issued patent except on the written approval of the other PARTIES to this Agreement, which approval shall not be unreasonably withheld. 
  

	 	d.	Patent Infringement and Third-Party Claims 

 Upon
the occurrence of any infringement or suspected or threatened infringement of any PARTY’s patents, or misappropriation or misuse of the know-how or confidential information related to such patents, any knowledgeable PARTY shall as soon as
practicable consult with the remaining PARTIES to determine what steps should be taken to prevent or terminate such infringement. 
  

 - 13 - 

 If a third-party asserts that a patent or other right owned by it is infringed by the manufacture of
PRODUCT or ISOMERS by POLI or INTERCHEM pursuant to this Agreement, the PARTY first obtaining knowledge of such a claim shall immediately provide the other PARTIES notice of such claim and the related facts in reasonable detail. Each PARTY agrees to
investigate the situation fully in collaboration with the other two PARTIES, and the PARTIES agree to discuss how best to control the defense of any such claim. In the event the PARTIES cannot agree on the defense of any such claim, LAYTON
BIOSCIENCE shall have the right, but not the obligation, to control such defense. POLI and INTERCHEM shall have the right to be represented separately by counsel of its own choice. 
 As to the enforcement of jointly owned patents, including actions against an infringer, the PARTIES shall consult with each other in good faith as to the
best manner in which to proceed. The PARTIES agree as a basic principle that in the case of such actions against infringers, the expenses incurred and damages awarded shall be for the account of the PARTY or PARTIES undertaking such actions to the
extent of their financial participation therein. 
 For the duration of this Agreement, and for any subsequent term of the same, LAYTON
BIOSCIENCE hereby agrees not take any patent infringement or other like action against POLI and INTERCHEM related to their manufacture and supply of ISOMERS that are the subject of patents issued to LAYTON BIOSCIENCE. 
 For the duration of this Agreement and any subsequent term of the same, and pursuant to grants of POLI and/or INTERCHEM licenses for know-how or patents
under the terms of this Agreement, POLI and INTERCHEM hereby agree not to take any patent infringement or other like action against LAYTON BIOSCIENCE or LAYTON BIOSCIENCE’s agents related to LAYTON BIOSCIENCE’s or its agents testing,
manufacture, and/or use of PRODUCT or ISOMERS that are the subject of know-how or patents issued and/or owned by POLI and/or INTERCHEM. 
  

 - 14 - 

	 	4.	PRICE AND PAYMENT 

  

	 	a.	Price 

 The initial selling price to LAYTON
BIOSCIENCE for the PRODUCT for deliveries is set forth in Exhibit C and shall be firm throughout the term of this Agreement. 
 Upon
marketing approval of any LAYTON BIOSCIENCE ISOMERS by the United States Food and Drug Administration, LAYTON BIOSCIENCE will enter good faith negotiations with POLI and INTERCHEM to determine and agree upon an initial selling price for such ISOMERS
to be firm throughout the subsequent twelve (12) months from the date an initial selling price for ISOMERS is agreed upon by the PARTIES. 
  

	 	b.	Payment 

 At the time of shipment by INTERCHEM or
POLI for eventual delivery to LAYTON BIOSCIENCE or its agent of any lot of PRODUCT or ISOMERS hereunder, INTERCHEM shall submit to LAYTON BIOSCIENCE an invoice setting forth the total amount of PRODUCT and/or ISOMERS being shipped to LAYTON
BIOSCIENCE and the amount due to INTERCHEM and POLI with respect to such volume of PRODUCT and/or ISOMERS. Accompanying each such invoice shall also be a certification that the PRODUCT and/or ISOMERS for which LAYTON BIOSCIENCE is being billed has
been produced fully in conformance with Exhibit B, cGMP, other requirements of this Agreement, and any other specifications the PARTIES agree upon regarding the quality of ISOMERS to be manufactured under this Agreement. 
  

 - 15 - 

 LAYTON BIOSCIENCE shall pay all undisputed invoices within thirty (30) days of receipt of invoice
and acceptance of PRODUCT or ISOMERS. INTERCHEM’s prices for the PRODUCT or ISOMERS do not include sales, use, excise, or similar taxes, which shall be the responsibility of LAYTON BIOSCIENCE. LAYTON BIOSCIENCE shall provide INTERCHEM with an
appropriate tax exemption certificate acceptable to the taxing authorities imposing such taxes, if LAYTON BIOSCIENCE wishes not to make such payments on its own behalf. 
  

	 	c.	INTERCHEM’s Compensation 

 INTERCHEM’s
compensation on the sale of PRODUCT or ISOMERS shall be included in the selling price of the PRODUCT or ISOMERS. 
  

	 	5.	PRODUCT QUALITY 

 All PRODUCT or ISOMERS supplied
hereunder shall be manufactured and supplied by POLI and INTERCHEM strictly in accordance with the specifications set forth in Exhibit Band current Good Manufacturing Practices (cGMP) as determined by the United States Food and Drug Administration
(FDA),and any other requirements the PARTIES mutually agree to in writing 

  

 - 16 - 

 
concerning any LAYTON BIOSCIENCE ISOMERS approved for marketing by the United States FDA. In addition, all PRODUCT or ISOMERS supplied hereunder shall be
manufactured and supplied by POLI and INTERCHEM strictly in accordance with all applicable rules and regulations of all applicable governmental regulatory authorities with jurisdiction over such manufacture and supply, including, but not limited to,
the United States FDA and the United States Drug Enforcement Administration (DEA). POLI and INTERCHEM may not subcontract with any third-party to perform any of POLI or INTERCHEM’s obligations under this Agreement without the prior written
consent of LAYTON BIOSCIENCE, which consent shall not be unreasonably withheld. 
 The PRODUCT and ISOMERS shall conform to the
specifications as set forth in Exhibit B attached hereto, except that any changes made pursuant to this Agreement and mutually agreed upon by all PARTIES in writing may modify these specifications. In addition to other warranties hereinafter set
forth, POLI warrants that all PRODUCT and ISOMERS sold to LAYTON BIOSCIENCE pursuant to this Agreement shall comply with the specifications of Exhibit B, any modifications thereto agreed to by the PARTIES, and FDA cGMPs. 
 POLI and INTERCHEM will take all steps necessary to ensure that they have the facilities, equipment, instrumentation, resources, and trained personnel to
provide all raw materials, manufacturing processes, in-process and product assays, analysis and other testing as compliance with cGMP standards may require in connection with POLI and INTERCHEM’s supply of PRODUCT and ISOMERS hereunder. POLI
and INTERCHEM shall provide a certificate of analysis for each lot of PRODUCT or ISOMERS supplied hereunder at the time of shipment. 
  

 - 17 - 

 POLI and INTERCHEM shall maintain complete and accurate documentation of all validation data, stability
testing data, batch records, quality control and laboratory testing and any other data required under cGMP and other requirements of any relevant regulatory authorities in connection with the manufacturing and supply of PRODUCT and ISOMERS
hereunder. POLI and INTERCHEM shall permit LAYTON BIOSCIENCE or its consultants to have access to any relevant records and data in connection with such manufacture, upon reasonable notice and during normal business hours. 
 POLI and INTERCHEM agree that they will not engage in any act which causes any PRODUCT or ISOMERS produced by POLI or INTERCHEM to become adulterated or
misbranded within the meaning of the United States Federal Food, Drug, and Cosmetic Act, as amended. 
  

	 	a.	Changes in Process 

 POLI reserves the right to
modify or change the process by which it manufactures the PRODUCT or ISOMERS. POLI will not manufacture PRODUCT or ISOMERS prepared by any such modified or changed process until it has notified LAYTON BIOSCIENCE and LAYTON BIOSCIENCE, POLI, and
INTERCHEM have received all necessary regulatory approvals. POLI further agrees to provide documentation concerning processing changes to the PRODUCT and ISOMERS and samples thereof produced by any such modified or changed process to LAYTON
BIOSCIENCE within thirty (30) days of their first production so that LAYTON BIOSCIENCE may verify that the PRODUCT and/or ISOMERS meets or exceeds all applicable quality standards. 
  

 - 18 - 

	 	6.	RECALL, WITHDRAWAL, OR FIELD CORRECTION 

 If LAYTON BIOSCIENCE
initiates or is required to initiate a product recall, withdrawal, or field correction with respect to, or if there is any governmental seizure of, any of its products containing any PRODUCT or ISOMERS supplied hereunder which action is due, in
whole or in part to the negligent or intentional wrongful act or omission of POLI or INTERCHEM in connection with the testing, manufacturing, release and control of PRODUCT or ISOMERS hereunder, LAYTON BIOSCIENCE will notify INTERCHEM or POLI
promptly of the details regarding such action, including providing copies of all relevant documentation concerning such action. POLI and INTERCHEM will assist LAYTON BIOSCIENCE in investigating any such situation and all regulatory contacts and
communications that are made and all activities concerning seizure, recall, withdrawal, or field correction will be jointly coordinated by LAYTON BIOSCIENCE, POLI, and, INTERCHEM, although the final decisions with respect to seizure, recall,
withdrawal, field correction or regulatory contacts and communications will be with LAYTON BIOSCIENCE. 
 If any such recall, withdrawal,
field correction, or seizure occurs due solely to the negligent or intentional wrongful act or omission of POLI or INTERCHEM in connection with the testing, manufacturing, release and control of PRODUCT or ISOMERS hereunder, then POLI and INTERCHEM
shall bear the full cost and expense including reasonable attorney=s and consultant=s fees, of any such seizure, recall, withdrawal, or field correction. If any such recall, withdrawal, field correction, or seizure occurs due solely to the negligent
or intentional wrongful act or omission of LAYTON BIOSCIENCE, including LAYTON BIOSCIENCE’s failure to properly ascertain whether PRODUCT or ISOMERS meets regulatory and product specifications, then LAYTON BIOSCIENCE shall bear the full cost
and expense of any such seizure, recall, withdrawal, or field correction. If more than one of the PARTIES contributes to the cause of a seizure, recall, withdrawal, or field correction, the cost and expenses thereof will be shared in proportion to
each PARTY’s contribution to the problem. 
  

 - 19 - 

 If any such recall, withdrawal, field correction, or seizure occurs due to a latent defect in the Product
(i.e., a defect other than the failure of the product to meet the established specifications in Exhibit B for the PRODUCT or similar specifications established for ISOMERS), as delivered to LAYTON BIOSCIENCE, that affects its quality or
functionality, then POLI/INTERCHEM and LAYTON shall equally share the cost and expense of any such seizure, recall, withdrawal, or field correction. 
  

	 	7.	FORCE MAJEURE 

 Neither INTERCHEM, POLI, nor LAYTON
BIOSCIENCE shall be liable or be in breach of any existing provision hereof for delays in delivery or failure to manufacture and deliver to the extent such delays are due to an event of force majeure; including: (1) causes beyond its reasonable
control, (2) acts of God, acts of civil or military authority, government controls or regulations, fire, strikes, accidents, floods, epidemics, quarantine restrictions, war, or (3) inability to obtain necessary labor, materials, components
or manufacturing facilities through regular channels due to causes beyond its reasonable control and only if the PARTY affected shall have used all reasonable efforts to avoid such occurrence and to remedy it promptly if it shall have occurred. In
the event of any such delay that impacts the performance of POLI or INTERCHEM under this Agreement, the date of delivery of PRODUCT or ISOMERS shall be deferred to a period up to but not to exceed the time attributable to the delay. If an event of
force majeure causes a failure or delay by POLI or INTERCHEM that exceeds forty-five (45) days, LAYTON BIOSCIENCE may, at its sole discretion, elect to obtain the PRODUCT or ISOMERS from another source for such period of time as such delay
continues. 
  

 - 20 - 

 In the event that an act of force majeure causes a failure in the manufacture or delay in the delivery of
PRODUCT or ISOMERS, once the direct effects of such an event are no longer present, POLI and INTERCHEM shall place priority on the manufacturing and supply of the deferred PRODUCT or ISOMERS for LAYTON BIOSCIENCE to the exclusion of all other
manufacturing and supply activities. 
 If there is a failure in the manufacture or delay in the delivery of PRODUCT due to an event of force
majeure, and the delivery of PRODUCT or ISOMERS is deferred by less than forty-five (45) days, there will be no alteration of the minimum total volume of PRODUCT requirement for the life of this Agreement as specified in Exhibit A, and any
minimum total volume requirement for ISOMERS as agreed upon by the PARTIES. However, if an event of force majeure causes the delivery of PRODUCT or ISOMERS to be deferred by more than forty-five (45) days, and such a deferral occurs within the
last sixty (60) days within a given yearly period as specified in Exhibit A, or any applicable twelve (12) month period per an agreed upon schedule for minimum total volume requirements for ISOMERS, the volume of PRODUCT or ISOMERS related
to such a deferral shall be deducted from the yearly minimum total volume of PRODUCT requirement for the year in which the deferral occurred pursuant to the schedule in Exhibit A or any applicable twelve (12) month period per an agreed upon
schedule for minimum total volume requirements for ISOMERS. 
  

 - 21 - 

 In the event that an act of force majeure causes a failure in the delay in the delivery of PRODUCT or
ISOMERS that exceeds ninety (90) days, LAYTON BIOSCIENCE may terminate this Agreement at its sole discretion, and in such a circumstance shall not be responsible for meeting any and all of the minimum volume of PRODUCT or ISOMERS requirements
as specified in Paragraph 2.a. and Exhibit A of this Agreement, or otherwise agreed upon by the PARTIES for ISOMERS. 
 Pursuant to the
PARTIES good faith negotiations concerning minimum total volume requirements as discussed in Paragraph 2.a. of this Agreement, the PARTIES will specifically delineate the effects of an event of force majeure effecting the delivery of ISOMERS to
LAYTON BIOSCIENCE on such minimum total volume requirements. 
  

	 	8.	INTELLECTUAL PROPERTY AND TECHNOLOGY TRANSFER 

  

	 	a.	Grants and Licenses 

 LAYTON BIOSCIENCE hereby
grants POLI and INTERCHEM a non-exclusive license without right to sublicense under the LAYTON BIOSCIENCE Patents for ISOMERS for the sole purpose of manufacturing the ISOMERS during the term of this Agreement. This license may not be assigned or
transferred without the prior written consent of LAYTON BIOSCIENCE. 
 POLI and/or INTERCHEM will hereby grant to LAYTON BIOSCIENCE or any
acquiring entity of LAYTON BIOSCIENCE a non-exclusive, royalty-free license, with a right to sublicense, any know-how, Patents, or Patent applications for manufacturing or processing PRODUCT or ISOMERS, under four circumstances: 1) if POLI and
INTERCHEM are unable to produce the PRODUCT 

  

 - 22 - 

 
or ISOMERS for any reason; 2) if POLI and INTERCHEM are unwilling to produce the PRODUCT or ISOMERS for any reason; 3) if POLI and INTERCHEM consistently
fail to meet regulatory and product specifications, including but not limited to U.S. Food and Drug Administrations Current Good Manufacturing Practices, and any specifications listed under the terms of this agreement at Exhibit B; or 4) termination
or expiration of this Agreement. If a disagreement arises as to the existence of a consistent failure to meet regulatory and product specifications, related U.S. Food and Drug Administration action (including but not limited to issuance of Warning
Letters or Form 483s) will serve as prima facie evidence thereof. In the absence of U.S. Food and Drug Administration action, the parties will submit to a mutually acceptable third party arbitrator, whose decision will be final in accordance with
Paragraph 26 of this agreement. The costs of the arbitration will be borne by the party against whom the arbitrator decides. 
 To the extent
that LAYTON BIOSCIENCE or any acquiring entity of LAYTON BIOSCIENCE sublicenses any POLI or INTERCHEM inventions, know-how, or Patents under this provision, the licensees of such sublicenses are limited to entities manufacturing pharmaceutical
products on behalf of LAYTON BIOSCIENCE, and any such sublicenses must state that the use of the POLI or INTERCHEM inventions, know-how, or Patents are limited to manufacturing pharmaceutical products for the direct benefit of LAYTON BIOSCIENCE or
any acquiring entity of LAYTON BIOSCIENCE. 
  

 - 23 - 

	 	b.	Drug Master Files 

 POLI and/or INTERCHEM will file
in a timely manner with the United States FDA, Type II Drug Master Files (DMF) regarding PRODUCT and ISOMERS, filed on behalf of POLI and/or INTERCHEM, relating to POLI and INTERCHEM’s Type II DMFs regarding the processes and materials used to
manufacture and supply PRODUCT and ISOMERS. 
  

	 	c.	Continuing Access to POLI and INTERCHEM Know-How and Technology Improvements 

 Upon the natural expiration of this Agreement, or if this Agreement is terminated for cause by LAYTON BIOSCIENCE as a result of the actions of POLI or INTERCHEM, as provided for in Paragraphs 25 and 14 of this
Agreement, POLI and INTERCHEM agree to provide technical advice and continuing access to the POLI and INTERCHEM intellectual property and know-how related to the manufacture and supply of PRODUCT and ISOMERS, including but not limited to providing
full access to and a copy of the contents of any DMFs filed by POLI or INTERCHEM with the United States FDA concerning PRODUCT or ISOMERS, and any related improvements to the manufacturing materials, equipment, procedures, or LAYTON BIOSCIENCE
patents or other technology. 
 Upon a material breach by LAYTON BIOSCIENCE of this Agreement commensurate with POLI and INTERCHEM’s
termination of the same, or a LAYTON BIOSCIENCE termination of this Agreement without cause (as described in Paragraph 25 of this Agreement) before the end of the initial term of this Agreement: (1) POLI and INTERCHEM agree to provide technical
advice and continuing access to the POLI and INTERCHEM intellectual property and know-how related to the manufacture and supply of PRODUCT and ISOMERS, including but not limited to providing full access to and a copy of the contents of any DMFs
filed by 

  

 - 24 - 

 
POLI or INTERCHEM with the United States FDA concerning PRODUCT or ISOMERS, and any related improvements to the manufacturing materials, equipment,
procedures, or LAYTON BIOSCIENCE patents or other technology, and (2) LAYTON BIOSCIENCE agrees to negotiate in good faith a reasonable fee or royalty rate, relative to the anticipated compensation to be paid to POLI and INTERCHEM under this
Agreement and the manufacturing start-up costs of the same, to compensate POLI and INTERCHEM for their start-up expenditures in furtherance of this Agreement and the opportunity costs of performing hereunder, prior to such termination or expiration
of this Agreement. 
  

	 	9.	CONFIDENTIALITY 

 LAYTON BIOSCIENCE, POLI, and
INTERCHEM shall maintain in confidence and not use or disclose to any third-party, except as is specifically contemplated herein or as is otherwise necessary to perform their respective obligations under this Agreement, and then only on a
confidential basis, any information, including, without limitation, business and technical information, experience or data regarding any facility, programs, laboratories, processes, products, costs, equipment operation, or customers, relating to the
manufacture, supply, and sale of PRODUCT hereunder. 
 LAYTON BIOSCIENCE, POLI, and INTERCHEM shall maintain in confidence and not use or
disclose to any third-party, any information, including, without limitation, business and technical information, experience or data regarding any facility, programs, laboratories, processes, products, costs, equipment operation, or customers,
relating to the manufacture, supply, and sale of ISOMERS hereunder. 
  

 - 25 - 

 Nothing herein shall prevent any PARTY to this Agreement from disclosing any information required by
statute or governmental regulations to be disclosed in a judicial or administrative proceeding after all reasonable legal remedies for maintaining such information in confidence have been practically exhausted. 
 Each PARTY agrees to retain in confidence proprietary information of the other disclosed pursuant to this Agreement Disclosed information shall not be
deemed confidential hereunder unless it is so identified and in written or graphic form, or reduced to written or graphic form within ten (10) days after disclosure; it is not now or later publicly known except through fault of the receiving
PARTY; and it is not known to the receiving PARTY at the time of disclosure other than through a confidential communication from the disclosing PARTY. Confidentiality of disclosed proprietary information and the obligation of confidentiality
hereunder shall survive termination of this Agreement for ten (10) years. 
  

	 	10.	REGULATORY COMPLIANCE 

 POLI and INTERCHEM will
comply in all material respects with all United States federal, state and local laws, regulations and standards applicable to production and supply by POLI and INTERCHEM and their performance of their obligations hereunder, including, but not
limited to, obtaining and maintaining any and all required permits, licenses, and certifications required by the United States FDA and Drug Enforcement Administration, and will file, maintain, and keep current United States FDA Drug Master Files
concerning the PRODUCT and ISOMERS. 
  

 - 26 - 

 POLI and INTERCHEM agree to promptly notify LAYTON BIOSCIENCE of any written or oral inquiries,
notifications, or inspection activities by any regulatory authority, including but not limited to the United States or Italy, in regard to the PRODUCT or ISOMERS. POLI and INTERCHEM will promptly furnish LAYTON BIOSCIENCE with all FDA inspection
reports and related correspondence directly related to and affecting their performance hereunder as and when such reports and correspondence become available to POLI or INTERCHEM. POLI and INTERCHEM will discuss with LAYTON BIOSCIENCE any regulatory
authority comments directly related to and affecting POLI or INTERCHEM’s performance hereunder and will give LAYTON BIOSCIENCE a reasonable opportunity to comment on POLI or INTERCHEM’s proposed response to such comments. POLI and
INTERCHEM agree to rectify promptly or resolve any deficiencies noted by a regulatory authority in a report or correspondence issued to the same, and which are based on POLI or INTERCHEM’s performance under this Agreement. In addition, POLI and
INTERCHEM shall promptly notify LAYTON BIOSCIENCE in the event of any communication from a regulatory authority, written or oral, which does not specifically relate to the PRODUCT or ISOMERS but which could reasonably be expected to result in a
disruption of POLI or INTERCHEM’s ability to supply PRODUCT or ISOMERS under this Agreement. 
 POLI and INTERCHEM will notify LAYTON
BIOSCIENCE immediately of any warning (including any FDA Form 483), Warning Letter, citation, indictment, claim, lawsuit or proceeding issued or instituted against POLI or INTERCHEM or any of its affiliates or of any revocation of any license or
permit issued to POLI or INTERCHEM or any of its affiliates, to the extent that any such occurrence relates directly to POLI or INTERCHEM’s performance hereunder. 
  

 - 27 - 

	 	11.	WARRANTIES 

  

	 	a.	INTERCHEM and POLI represent and warrant that: 

  

	 	(l)	they have full right and power to enter into this Agreement and perform in accordance with its terms; 

  

	 	(2)	The PRODUCT will conform to the specifications in Exhibit B, FDA cGMPs, and with any and all other requirements and specifications the PARTIES mutually agree upon concerning
ISOMERS; 

  

	 	(3)	the PRODUCT and ISOMERS shall be in good and merchantable condition and fit for the purpose intended; 

  

	 	(4)	the PRODUCT and ISOMERS shall be manufactured and delivered in compliance with all applicable United States state and federal laws and regulations and guidelines specifically
without limitation, the provisions of the United States Federal Food, Drug, and Cosmetic Act (FFDCA), including cGMPs; 

  

	 	(5)	they have good title to applicable patents as specified in-Paragraph 3 of this Agreement; 

  

	 	(6)	there is no claim, suit, proceeding, or investigation pending or, to the knowledge of POLI or INTERCHEM, threatened against POLI or INTERCHEM or any of their collective affiliates
which might prevent or interfere with POLI or INTERCHEM’s performance under this Agreement; 

  

 - 28 - 

	 	(7)	the PRODUCT and ISOMERS sold and supplied hereunder will not be: (i) adulterated or misbranded within the meaning of the United States FFDCA, as amended, or within the meaning
of any applicable state or municipal law in which the definitions of adulteration and misbranding are substantially identical with those contained in the FFDCA, (ii) manufactured or sold in violation of the United States Federal Controlled
Substances Act, as amended, or any applicable state law, (iii) manufactured or sold in violation of any of the provisions of the United States Fair Labor Standards Act of 1938, as amended, (iv) manufactured or sold in violation of the
Occupational Safety and Health Act of 1970, as amended, (v) manufactured in violation of any applicable federal, state, or local environmental law or regulation, in either the United States or Italy, or (vi) manufactured in violation of
any agreement, judgement, order, or decree to which POLI or INTERCHEM are a PARTY; 

  

	 	(8)	they will file in a timely manner with the United States FDA, Type II Drug Master File (DMF) regarding PRODUCT and ISOMERS, maintain and keep current this DMF, and not interfere in
any way with LAYTON BIOSCIENCE’s references to this DMF pursuant to LAYTON BIOSCIENCE investigational new drug applications, new drug applications (NDAs), supplemental NDAs, or other applications and requests submitted to the United States FDA;

  

	 	(9)	neither POLI, INTERCHEM, nor their collective affiliates, nor any member of their respective staffs, have been disqualified or debarred by the FDA for any purpose;

  

	 	(10)	neither POLI, INTERCHEM, nor their collective affiliates, nor any member of their respective staffs have been charged with or convicted under United States federal law for conduct
relating to the development or approval, or otherwise relating to the regulation of any drug product under the Generic Drug Enforcement Act of 1992 or any other relevant statute, law or regulation; and 

  

 - 29 - 

	 	(11)	the execution and delivery of this Agreement has been duly authorized, and upon execution and delivery shall be a valid and binding obligation of POLI and INTERCHEM.

  

	 	b.	LAYTON BIOSCIENCE represents and warrants that it has the full right and power to enter into this Agreement and perform in accordance with its terms, and that the execution and
delivery of this Agreement has been duly authorized, and upon execution and delivery shall be a valid and binding obligation of LAYTON BIOSCIENCE. 

  

	 	12.	FACILITY ACCESS 

 LAYTON BIOSCIENCE, through its
employees, consultants, or other representatives, will have the right during normal business hours and upon advance arrangement with POLI or INTERCHEM to inspect POLI and INTERCHEM’s manufacturing operations to determine whether or not POLI and
INTERCHEM are complying in all respects with their obligations hereunder. LAYTON BIOSCIENCE warrants that all such inspections and audits shall be carried out in a manner calculated not to unreasonably interfere with POLI or INTERCHEM’s conduct
of business and to insure the continued confidentiality of POLI and INTERCHEM’s business and technical information. Further, LAYTON BIOSCIENCE agrees to comply with all of POLI and INTERCHEM’s safety and security measures during any visits
to the POLI or INTERCHEM facilities. 
  

 - 30 - 

	 	13.	INDEMNIFICATION 

 POLI and INTERCHEM, on behalf of
themselves and their respective affiliates, hereby agree to indemnify, defend, and hold harmless LAYTON BIOSCIENCE and its affiliates from and against any and all demands, claims, actions, causes of action, assessments, losses, damages, injuries,
liabilities, costs and expenses, including without limitation, interest, penalties and reasonable attorneys fees and expenses (collectively Damages) asserted against, resulting to, imposed upon or incurred by LAYTON BIOSCIENCE, its employees or its
affiliates, directly or indirectly related to, arising out of, or resulting from: 
  

	 	(i)	any breach or failure of any of the representations, warranties, and covenants of POLI and INTERCHEM contained herein, including (without limitation) any breach or failure by POLI
or INTERCHEM to perform any obligations contained hereunder; 

  

	 	(ii)	the negligence or willful misconduct of POLI or INTERCHEM or their respective officers, employees, or agents; 

  

	 	(iii)	any defect in the manufacture of the PRODUCT or ISOMERS, to the extent not caused by fault attributable to LAYTON BIOSCIENCE or its agents or third-party contractors; or

  

	 	(iv)	any failure of POLI or INTERCHEM to observe or comply in all material respects with any laws, rules, or regulations directly related to POLI or INTERCHEM’s performance
hereunder. 

  

 - 31 - 

 LAYTON BIOSCIENCE, on behalf of itself and its affiliates, hereby agrees to indemnify, defend, and hold
harmless POLI and INTERCHEM and their collective affiliates from and against any and all Damages asserted against, resulting to, imposed upon or incurred by POLI or INTERCHEM or their collective employees or affiliates, directly or indirectly
related to, arising out of, or resulting from: 
  

	 	(i)	any breach or failure of any of the representations, warranties, and covenants of LAYTON BIOSCIENCE contained herein; 

  

	 	(ii)	any failure of LAYTON BIOSCIENCE to observe or comply in all material respects with any laws, rules, or regulations directly related to LAYTON BIOSCIENCE’s performance
hereunder, including the failure to adequately inspect for deviations from the specifications set forth at Exhibit B of this Agreement, or agreed-upon specifications related to the ISOMERS; or 

  

	 	(iii)	LAYTON BIOSCIENCE’s, its agents, distributors, or customers use, processing, transportation, possession, disposal, or sale of any finished dosage product manufactured by LAYTON
BIOSCIENCE, whether containing PRODUCT or ISOMERS or not, and whether used alone or in combination with any other material; provided, however, the foregoing shall not apply in circumstances which give rise to POLI or INTERCHEM’s
obligation to indemnify, defend, and hold harmless LAYTON BIOSCIENCE, its employees and affiliates pursuant to this Paragraph. 

 Each indemnitee hereunder shall notify the indemnitor in writing within ten (10) working days after receipt of written notice that the indemnitee has been sued or that suit is reasonably imminent, but no indemnitee shall lose
indemnification rights hereunder by failing to give the indemnitor such a notice unless such failure materially and adversely affects the indemnitor’s ability to defend. 

  

 - 32 - 

 
The indemnitor shall have the sole right to select defense counsel and to direct the defense or settlement of any such claim or suit, as long as it bears the
costs thereof. In the event that representation of both the indemnitor and the indemnitee by the same counsel would be a conflict of interest for such counsel, an indemnitee may select its own independent counsel without relieving the indemnitor of
its obligations under this section. Under no circumstances, however, shall any indemnitee settle or otherwise compromise any suit or claim without either bearing the cost thereof or obtaining the indemnitor’s prior written consent. 

 

	 	14.	BANKRUPTCY 

 If any proceedings in bankruptcy or in
reorganization, or for the appointment of a receiver or trustee for all or a substantial portion for the assets of any PARTY to this Agreement, or any other like proceedings, under any law for the relief of debtors shall be instituted by or against
any PARTY hereto and are not dismissed within ninety (90) days, this Agreement shall immediately terminate. The PARTIES shall give each other immediate written notice of the institution of such proceedings as hereinafter set forth in Paragraph
16 of this Agreement. 
  

	 	15.	ASSIGNMENT 

 Except in connection with the sale or
transfer of all or substantially all of any PARTY’s assets, by merger or otherwise, no PARTY shall assign this Agreement without the express written approval of the other PARTIES, which approval shall not be unreasonably withheld. 

 

 - 33 - 

	 	16.	NOTICES 

 Any notice or request required or
permitted to be given under or in connection with this Agreement shall be deemed to have been sufficiently given if in writing and sent by certified mail, return receipt requested; or prepaid telegram, to such PARTY, at the address set forth for
such PARTY below. If a PARTY changes its address, written notice shall be shall be given promptly to the other PARTIES of the new address. Notice shall be deemed given on the day it is sent (in the case of delivery by method other than hand
delivery) or the date of delivery (in the case of delivery by hand) in accordance with the provisions of this Paragraph. The addresses for the notices are as follows: 
  

			
	 If to LAYTON BIOSCIENCE, INC.:
	  	LAYTON BIOSCIENCE, INC.
		  	709 East Evelyn Road
		  	Sunnyvale, California 94086
		  	Attention: Gary L. Snable, President & CEO
		
	 If to INTERCHEM:
	  	INTERCHEM CORPORATION
		  	120 Route 17 North
		  	Paramus, New Jersey 07652
		  	Attention: Ronald J. Mannino, Chairman
		
	 If to POLI INDUSTRIAL CHIMICA:
	  	POLI INDUSTRIA CHIMICA
		  	Via Volturno 48-20089
		  	Quinto DeStampi
		  	Rozzano, Milano
		  	Italy
		  	 Attention: Dr. Alberto Mangia – Managing

		  	Director
		
	 With a copy to:
	  	Stephen A. Janetta
		  	Morgan, Lewis & Bockius LLP
		  	1701 Market Street
		  	Philadelphia, Pennsylvania 19103-2921

  

 - 34 - 

	 	17.	WAIVER 

 The failure by any PARTY to exercise its
rights hereunder or to enforce any of the terms or conditions of this Agreement on any occasion shall not constitute or be deemed a waiver of that PARTY’s rights thereafter to exercise any rights hereunder or to enforce each and every term and
condition of this Agreement. 
  

	 	18.	MODIFICATIONS 

 This Agreement may not be amended or
modified except by a writing specifically referring to this Agreement and executed by duly authorized representative of all PARTIES. The obligations of the PARTIES are governed by the terms and conditions of this Agreement and none of the general
terms and conditions of any LAYTON BIOSCIENCE purchase order or any POLI or INTERCHEM acknowledgment of any substantially similar documents of either PARTY will in any case be controlling or supersede the provisions hereof. 
  

 - 35 - 

	 	19.	OTHER DOCUMENTS 

 Unless specifically agreed to the
contrary by the PARTIES in writing, if there is any inconsistency between the provisions of the Agreement and any purchase order or other documents passing between the PARTIES, the provisions of this Agreement shall control. 
  

	 	20.	GOVERNING LAW 

 This Agreement shall be governed and
interpreted in accordance with the laws of the State of New Jersey. 
  

	 	21.	SEVERABILITY 

 If and to the extent that any court
of competent jurisdiction holds a provision or part of this Agreement to be invalid or unenforceable, such holding shall, to the extent possible, in no way affect the validity of the remainder of this Agreement. 
 In the event that any part of any of the covenants, sections, or provisions herein may determined by a court of law or equity to be overly broad or
against applicable precedent or public policy, thereby making such covenants, sections or provisions invalid or unenforceable, the PARTIES shall attempt to reach agreement with respect to a valid and enforceable substitute for the deleted
provisions, which shall be as close in its intent and effect as possible to the deleted provisions. 
  

 - 36 - 

	 	22.	HEADINGS 

 Headings in this Agreement are included
for ease of reference only and shall have no legal effect. 
  

	 	23.	ENTIRE AGREEMENT 

 This Agreement sets’ forth
the entire Agreement and understanding between the PARTIES as to the subject matter hereof and merges all prior discussions and negotiations between them, and none of the PARTIES shall be bound by any conditions, definitions, warranties,
understandings or representations with respect to such subject matter other than as expressly provided herein or as duly set forth on or subsequent to the date hereof in writing and signed by a proper and duly authorized officer or representative of
the PARTY to be bound hereby. 
  

	 	24.	PARTIES RELATIONSIDP 

 No PARTY shall hold itself
out to third-parties as possessing any power or authority to enter into any contract or make any commitment on behalf of the other PARTY. It is not intended that this Agreement create any agency, partnership or joint employer relationship, and that
POLI and INTERCHEM shall be deemed to be independent contractors of LAYTON BIOSCIENCE. 
  

 - 37 - 

	 	25.	TERMINATION 

 Pursuant to Paragraph 2.e. of this
Agreement, this Agreement shall remain in full force and effect for said term unless this Agreement is terminated. This Agreement may be terminated for a material breach which is not remedied within sixty (60) days of written notice of the
breach. Written notice of the alleged material breach is a condition precedent to acting under the material breach provisions of this section. Pursuant to Paragraph 26 of this Agreement, the P ARTY accused of the material breach may request
arbitration if the same issues a written notice to the other PARTIES to this Agreement. The arbitration may determine whether a breach has occurred or if the breach is material. The decision of the arbitrators shall be final. This Agreement may also
be terminated pursuant to the bankruptcy provisions in Paragraph 14 of this Agreement, or any other provisions of this Agreement which explicitly provide for termination. 
 The representations and warranties of the PARTIES hereunder, covenants which by their terms have effect after the termination or expiration hereof, and the PARTIES’ indemnification, confidentiality, intellectual
property, and technology transfer obligations shall survive termination or expiration of this Agreement. Upon termination, the PARTIES, at the request of another PARTY, shall return promptly to an owner all technical and promotional material in its
possession related to this Agreement and the manufacture and supply of PRODUCT or ISOMERS; all copies of such material shall remain confidential pursuant to Paragraph 9 of this Agreement. 
 In the event of any termination of this Agreement, for whatever reason, POLI and INTERCHEM shall, notwithstanding the effective date of any termination,
complete any orders for PRODUCT or ISOMERS that were made by LAYTON BIOSCIENCE prior to such date, and LAYTON BIOSCIENCE shall pay POLI and INTERCHEM for any PRODUCT or ISOMERS produced in accordance with such orders at the then applicable PRODUCT
or ISOMERS prices in effect on the effective date of the termination hereunder. 
  

 - 38 - 

	 	26.	ARBITRATION 

 It is anticipated that during the
existence of this contract issues may arise upon which the PARTIES may not agree. In the event of a disagreement, which cannot be resolved by negotiation, any PARTY may request arbitration. Arbitration shall be the exclusive means of resolving
disputes under this Agreement’ which cannot be resolved by mutual negotiation. The decision of the arbitrators shall be final and may not be appealed. Any arbitration hearing will be conducted in Philadelphia, Pennsylvania or New York, New
York, 
  

	 	a.	Number of Arbitrators 

 In the event of a dispute in
which two (2) of the PARTIES have reached an agreement, there shall be three (3) arbitrators; one (1) selected by the two (2) PARTIES in agreement and one (1) by the other PARTY. These two arbitrators shall select a third
arbitrator. If the arbitrators cannot agree on the third arbitrator, one shall be selected by the American Arbitration Association (AAA). In the event none of the PARTIES agree, there shall be five (5) arbitrators, one (1) selected by each
PARTY and two (2) selected by the arbitrators. In the event the arbitrators cannot agree on the other two arbitrators, the AAA shall select the same. 
  

 - 39 - 

	 	b.	Arbitration Rules 

 The arbitration shall be
conducted by the AAA under its rules in effect at the time the arbitration is requested. The loser of the arbitration shall pay the cost of the arbitration but not the legal costs incurred by the other PARTIES. The arbitrators may apportion the
costs as they may deem fair and equitable. 
 IN WITNESS THEREOF, the PARTIES hereto have executed this Agreement as of the date set forth above. 

 

									
	INTERCHEM CORPORATION	 		 	POLI INDUSTRIA CHIMICA
					
	BY:	 	/s/ Ronald J. Mannino	 		 	BY:	 	/s/ Alberto Mangia
		 	    Ronald J. Mannino,	 		 		 	    Dr. Alberto Mangia,
		 	    Chairman	 		 		 	    Managing Director
			
	DATE: July 18, 2001	 		 	DATE: July 20th, 2001

  

			
	LAYTON BIOSCIENCE, INC.
		
	BY:	 	/s/ Robert Alonso
		 	    Robert Alonso
		 	    Vice President

 DATE: July 11, 2001 
  

 - 40 -Second Amendment to Supply Agreement

 Exhibit 10.22 
 CONFIDENTIAL TREATMENT REQUESTED 
 BY RUBICON TECHNOLOGY, INC. 
 SECOND AMENDMENT TO SUPPLY AGREEMENT 
 by and
between 
 PEREGRINE SEMICONDUCTOR CORP. 
 and 
 RUBICON TECHNOLOGY, INC. 
 This Second Amendment (this “Amendment”) further amends that certain Supply Agreement by and between Peregrine Semiconductor Corp., with offices at 9450 Carroll Park Drive, San Diego, California 92121 (“Buyer”) and
Rubicon Technology, Inc., with offices at 9931 Franklin Avenue, Franklin Park, Illinois 60131 (“Seller”), dated as of March 26, 2007 (the “Agreement”), and is made by and between the parties to the Agreement as of
November 25, 2008 (the “Effective Date”). 
 RECITALS 
 A. Buyer and Seller are parties to the Agreement, which provides for the purchase and sale in 2008 of Products, as defined therein, as amended by an
agreement of the parties as of August 22, 2008 that modified the volume of Product purchases and sales in 2008 and provided for certain Product purchases and sales in 2009 (the “Amended Agreement”). 
 B. Buyer and Seller now desire to amend the Amended Agreement to provide for an agreement between the parties with respect to Product purchases and sales
in 2008, 2009, 2010, and 2011. 
 C. Buyer also currently owes Seller $2,906,250, which includes certain amounts for Products purchased under
the Amended Agreement. In connection with payment of amounts owed, Buyer and Seller also desire to provide for a closer strategic relationship between the two companies pursuant to which Seller will become an investor in Buyer as part of
Buyer’s recent Series D1 Preferred Stock financing (“D1 Financing”) and Buyer will issue to Seller Series D1 Preferred Stock (the “Series D1 Stock”) in the amount of $2,000,000 pursuant to an agreement entered into as of the
date of this Amendment and will pay to Seller $906,250 on the Effective Date of this Amendment. 
 Now, therefore, for the consideration
described in the recitals above and the mutual benefits to be derived by the parties from this Amendment, the sufficiency of which is hereby acknowledged, Buyer and Seller agree to further amend the Agreement as follows: 
 1. Definitions. Unless otherwise expressly provided in this Amendment, each capitalized term used in this Amendment has the same meaning as
provided in the Amended Agreement. 
  

 B-1 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL TREATMENT REQUESTED 
 BY RUBICON TECHNOLOGY, INC. 
  
 2. Revision of Product Delivery and Acceptance Obligation. 
 (a) The Product quantities and delivery
amounts described in the Amended Agreement are hereby revised such that: 
 (i) During 2008: Seller shall have no obligation to
manufacture and sell to Buyer and Buyer shall have no obligation to purchase or accept delivery from Seller of any additional Products during 2008 as provided in the Amended Agreement; 
 (ii) During 2009: Seller shall manufacture and sell to Buyer and Buyer shall purchase from Seller and accept delivery of the greater of [***]
[***] sapphire wafers (“Wafers”) or 70% of Buyer’s monthly Wafer purchases (for purposes of this Amendment, “Buyer’s monthly Wafer purchases” shall include any Wafers purchased by Buyer for use by Buyer’s
fabricators or other third parties) in each month of 2009; 
 (iii) During 2010: Seller shall manufacture and sell to Buyer and Buyer
shall purchase from Seller and accept delivery of 70% of Buyer’s monthly Wafer purchases, up to [***] per month, and Seller shall manufacture and sell to Buyer and Buyer shall purchase from Seller and accept delivery of 50% of Buyer’s
monthly Wafer purchases for quantities above [***] Wafers per month in each month of 2010; and 
 (iv) During 2011: Seller shall
manufacture and sell to Buyer and Buyer shall purchase from Seller and accept delivery of not less than 50% of Buyer’s monthly Wafer purchases. 
 (b) Seller is hereby authorized to ship to Buyer [***] Wafers in each month of 2009 without further order from Buyer and, if Buyer shall require more than such minimum number of Wafers for any month, Buyer shall
deliver a notice to Seller not less than 90 days before the first day of the month in which the greater number of Wafers is to be shipped (the “Purchase Month”), advising Seller of the total number of Wafers that Buyer desires to be
shipped in the Purchase Month. Wafers shipped in 2010 and 2011 must be shipped pursuant to Buyer’s purchase orders which shall be delivered to Seller not less than 90 days before the scheduled delivery date. 
 (c) Seller will have the right, upon reasonable notice during business hours to audit and copy Buyer’s books and records relating to Wafer purchases
from any source, the use of Wafers in Buyer’s products and the sale of such products and to interview Buyer’s personnel with respect to the same. Seller will bear the cost of such audits unless Seller determines pursuant to an audit that
Buyer has purchased less than 50% of its Wafer requirements during any month, in which case, Buyer shall reimburse Seller for all of its audit costs and shall, within 45 days or such longer time period as Seller may require, purchase the number of
Wafers that Buyer was obligated to purchase from Seller during any month in which Buyer failed to purchase at least 50% of its Wafer requirements from Seller. 
  

 B-2 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL TREATMENT REQUESTED 
 BY RUBICON TECHNOLOGY, INC. 
  
 3. Price and Specifications. 
 (a) Buyer shall pay Seller [***] per Wafer for the first [***] Wafers
delivered pursuant to this Amendment through 2010. 
 (b) Pricing in 2009 and 2010 for Wafers delivered after [***] Wafers have been
delivered pursuant to this Amendment will be as follows: 
  

							
	  	 	 Quarterly Volume
	  	 Price per Wafer
	  	 
		 	 £ [***]   
	  	[***]	  	
		 	 [***]
	  	[***]	  	
		 	 [***]
	  	[***]	  	
		 	 [***]
	  	[***]	  	
		 	 [***]
	  	[***]	  	
		 	 [***]
	  	[***]	  	
		 	 [***]
	  	[***]	  	

 For clarity, the first pricing reduction, from [***] to [***], will apply to the first Wafer
delivered after [***] Wafers are delivered. However, further incremental price decreases will occur only if the total quantity for each pricing increment is purchased during a calendar quarter (for purposes of this Amendment, a “calendar
quarter” means January – March, April – June, July – September, or October – December). Therefore, if after [***] Wafers are delivered and Buyer does not order more than [***] Wafers in any calendar quarter, then the price
per Wafer will remain at [***]. 
 (c) Commercially reasonable pricing (based upon previous pricing, anticipated quantities for 2011, and
market conditions) for the Wafers to be purchased by Buyer from Seller in 2011 will be agreed upon by the parties before September 30, 2010. 
 (d) Seller will provide a [***] discount to Buyer for each Wafer delivered to Buyer pursuant to this Amendment that does not meet grade 1 specifications as defined in Attachment A hereto, up to the first [***] Wafers delivered. After [***]
Wafers are delivered, all Wafers delivered to Buyer shall meet the grade 1 specifications. 
 4. Issuance of Series D1 Shares and Payment. On the
Effective Date: (a) Buyer will transfer to Seller 1,345,444 unencumbered shares of Series D1 Stock (valued at a total of $2,000,000) and Seller will execute all agreements and other documents executed by other investors in Buyer’s D1
Financing; and (b) Buyer will pay to Seller by electronic funds transfer in accordance with instructions to be provided to Buyer by Seller, $906,250. If the foregoing conditions precedent (the “Conditions”) to the effectiveness of
this Amendment are not met, then this Amendment will be void and of no effect. If the foregoing Conditions are met, then Buyer’s obligation to pay Seller $2,906,250 will have been satisfied. 
  

 B-3 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL TREATMENT REQUESTED 
 BY RUBICON TECHNOLOGY, INC. 
  
 5. Release and Waiver. Buyer and Seller agree that effective upon the Effective Date and subject to the completion of the Conditions in Section 4 above, Seller shall have no obligation to sell and Buyer shall have no obligation
to purchase the Products in the quantities set forth on Attachment A to the Agreement or in the Amended Agreement and neither Seller nor Buyer shall have any liability or obligation to the other party with respect to the failure of Buyer to purchase
or Seller to sell the quantity of Products set forth in the Amended Agreement. Buyer and Seller further agree that as of the Effective Date and subject to the completion of the Conditions in Section 4, Buyer shall have paid Seller in full for
all Products purchased and delivered under the Amended Agreement and shall have no further payment obligation with respect to any Products delivered by Seller to Buyer under the Amended Agreement as of the Effective Date. Upon the Effective Date and
subject to the completion of the Conditions in Section 4, Buyer and Seller each hereby agree, to the fullest extent permitted by applicable law, to waive, release and promise never to assert any claims or causes of action, whether or not now
known, against the other party with respect to the failure of Buyer to purchase or failure of Seller to sell the Products in the quantities set forth on Attachment A to the Agreement or in the Amended Agreement or with respect to the payment of any
Products delivered by Seller to Buyer prior to the Effective Date. 
 6. No Other Changes. Except as is expressly provided in this Amendment, the
Amended Agreement is not amended or revised in any other way and remains in full force and effect and this Amendment shall be considered a part thereof. 
 IN WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this Amendment as of the Effective Date above. 
  

			
	 Rubicon Technology, Inc.

		
	By:	 	 /s/ Raja Parvez

		 	Raja Parvez, President & CEO
	
	 Peregrine Semiconductor Corp.

		
	By:	 	 /s/ Jim Cable

		 	Jim Cable, President & CEO

  

 B-4 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 CONFIDENTIAL TREATMENT REQUESTED 
 BY RUBICON TECHNOLOGY, INC. 
  
 ATTACHMENT A 
 TO 2ND AMENDMENT TO RUBICON/PEREGRINE SUPPLY AGREEMENT 
  

	1	Purpose 

 This document specifies the characteristics of [***]
Sapphire Wafers. 
  

	2	Scope 

 This document defines the requirements for purchase of [***]
Sapphire Wafers for Peregrine Semiconductor and its foundries. 
  

	3	Authority and Responsibility 

 This document is controlled by the
Operations Department of Peregrine Semiconductor. 
  

	4	References 

 SEMI MF1390-0707 - Test Method for Measuring Warp on
Silicon Wafers by Automated Non-Contact Scanning  
 SEMI MF534-0707 - Test Method for Bow of Silicon Wafers  
 SEMI MF657-0707 - Test Method for Measuring Warp and Total Thickness Variation on Silicon Wafers by Non-Contact Scanning  
 SEMI MF1530-0707 - Test Method for Measuring Flatness, Thickness, and Total Thickness Variation on Silicon Wafers by Automated Non-Contact Scanning  
 SEMI M13-1103 - Specification for Alphanumeric Marking of Silicon Wafers  
 SEMI AUX015 - SEMI OCR Character Outlines 
  

	5	Definitions 

  

	 	5.1	[***] 

  

	 	5.2	[***] 

  

	 	5.3	[***] 

  

	6	Specification 

 Rubicon Proposal 19-Sep-08 

  

 B-5 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 150 mm, Grade 1, Sapphire Specification 
 (Part 1) 
  

																	
	 ITEM
	  	CHARACTERISTIC	  	 UNITS
	  	TARGET	  	TOLERANCE	  	MEASUREMENT
METHOD	  	FREQUENCY	  	 NOTE

	MANUFACTURING METHODS	  	GROWING METHOD	  		  		  		  		  		  	[***]
		  	SURFACE ORIENTATION	  	degree	  	[***]	  	[***]	  	XRD	  	All wafers	  	[***]
	PHYSICAL DIMENSIONS	  	WAFER DIAMETER	  	mm	  	[***]	  	[***]	  	Micrometer	  	5 wfrs/lot	  	
	  	WAFER
REGISTRATION	 	SEMI FLAT	  	mm	  	[***]	  	[***]	  	Micrometer	  	5 wfrs/lot	  	
	  	 	JEITA FLAT	  	mm	  	[***]	  	[***]	  	Micrometer	  	5 wfrs/lot	  	
		  	THICKNESS	  	μm	  	[***]	  	[***]	  	Micrometer	  	5 wfrs/lot	  	
		  	FLAT LOCATION	  	degree	  	[***]	  	[***]	  	XRD	  	10 wfrs/lot	  	See Figure A.
	FLATNESS	  	QUALITY AREA	  		  		  		  		  		  	[***]
		  	GLOBAL
FLATNESS	 	TOTAL THICKNESS VARIATION	  	μm	  	[***]	  		  	Tropel or
equivalent	  	All wafers	  	[***]
		  	 	FOCAL PLANE DEVIATION (GF3D)	  	μm	  	[***]	  		  	  	  	[***]
		  		 	WARP	  	μm	  	[***]	  		  		  		  	[***]
		  		 	BOW	  	μm	  	[***]	  		  		  		  	[***]
		  	SITE
FLATNESS	 	SFQR	  	μm	  	[***]	  		  	Tropel or
equivalent	  	All wafers	  	[***]
		  	 	SITE SIZE	  	mm	  	[***]	  		  	  	  
		  	 	PERCENT USABLE AREA	  	%	  	[***]	  		  	  	  
	EDGE BEVEL	  	BEVEL METHOD	  		  		  		  		  		  	[***]
	  		 	  1. EDGE CORNER SHAPE	  		  	[***]	  		  	Profile
Projector	  	1 wafer
per lot	  	See Figure B.
	  		 	  2. BEVEL EDGE SHAPE	  		  	[***]	  		  	  	  
	  		 	  3. BEVEL WIDTH @ FRONT	  	μm	  	[***]	  	[***]	  	  	  
		  		 	  4. BEVEL WIDTH @ BACK	  	μm	  	[***]	  	[***]	  	  	  
		  		 	  5. EDGE THICKNESS	  	μm	  	[***]	  	[***]	  		  		  	
		  	EDGE CHIPS	 	QUANTITY	  	count	  	[***]	  		  	Microscope	  	All wafers	  	[***]
		  		 	WIDTH	  	mm	  	[***]	  		  	  	  
		  		 	LENGTH	  	mm	  	[***]	  		  	  	  
	MATERIAL DEFECT	  	DISLOCATION DENSITY	  	count/cm2	  	[***]	  		  	microscope	  	1 per 6
months	  	[***]
	  	BUBBLES	  	count	  	[***]	  		  	Visual	  	All wafers	  	
	  	SLIPS, TWINS & LINEAGE	  	count	  	[***]	  		  	Visual	  	All wafers	  	[***]
	  	CRACKS & FRACTURES	  	count	  	[***]	  		  	Visual	  	All wafers	  	[***]
	  	METALLIC
IMPURITY	 	Na, K, Ca, Cr, Fe, Ni, Z	  	ppm	  	[***]	  		  	ICP-MS	  	1 per 12
months	  	

  

 B-6 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

																	
	 ITEM
	  	 CHARACTERISTIC
	  	 UNITS
	  	 TARGET
	  	 TOLERANCE
	  	 MEASUREMENT
 METHOD
	  	 FREQUENCY
	  	 NOTE

	FRONT SURFACE	  	 SURFACE
 ROUGHNESS
	  	 Ra
	  	 Å
	  	 [***]
	  		  	AFM	  	1 wafer/lot	  	 [***]

		  	SCRATCH	  		  	 [***]
	  		  	Microscope	  	All wafers	  	 [***]

		  	PITS, SPOTS, DIMPLES & STAINS	  		  		  	 [***]
	  		  	Microscope	  	All wafers	  	 [***]

		  	GROSS CONTAMINATION	  		  	 [***]
	  		  	Microscope	  	All wafers	  	 [***]

		  	PARTICULATE	  	 Larger than 0.3 μm
	  	 count
	  	 [***]
	  		  	Candela CS10	  	All wafers	  	 [***]

		  	  	 0.3 to 0.5 μm
	  	 count
	  	 [***]
	  		  	  	  
		  	 SURFACE
 METALLIC
CONTAMINATION
	  	 Na
	  	 1/cm2

	  	 [***]
	  		  	ICP mass spectroscopy	  	 1 wafer per
 half year.
	  	
		  	  	 K, Ca, Ti, Cr, Cu,
 Zn, Ni, Fe
	  	 1/cm2

	  	 [***]
	  		  	TXRF	  	 1 wafer per
 wet clean solution change
	  	
	BACK SURFACE	  	 SURFACE
 ROUGHNESS
	  	 Ra
	  	 μm
	  	 [***]
	  	 [***]
	  	Kosaka	  	 1 wafer per
 Lap batch
	  	 [***]

		  		  	 Ra
	  	 μm
	  	 [***]
	  	 [***]
	  	 Tencor
 Alpha-Step
	  	 1 wafer per
 Lap batch
	  
		  	SCRATCHES	  		  	 [***]
	  		  	Microscope	  	All wafers	  	
		  	BUMPS	  		  	 [***]
	  		  	Naked eye	  	All wafers	  	
		  	VISIBLE CONTAMINATION	  		  	 [***]
	  		  	Naked eye	  	All wafers	  	
		  	SAW MARKS	  		  	 [***]
	  		  	Naked eye	  	All wafers	  	
		  	 WATER STAINS, WATER SPOTS,
 SLURRY RESIDUE

	  		  	 [***]
	  		  	Naked eye	  	All wafers	  	
		  	TRANSPARENT AREA	  		  	 [***]
	  		  	Naked eye	  	All wafers	  	
		  	WAFER MARKING	  		  		  		  	 Lumonics
 or equivalent
	  	All wafers	  	 [***]

  

 B-7 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

 Figure A [***] 
 Figure C [***] 
 Figure B [***] 
  

 B-8 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 

	7	Quality 

  

	 	7.1	Gauge Study: The supplier shall be required to perform a gauge study on all equipment used for obtaining quality data. 

  

	 	7.2	Quality Data: 

  

	 	7.2.1	Lot Data: Particle and flatness data for each lot shall be sent electronically to Peregrine at the time the lot is shipped from the supplier. 

  

	 	7.2.2	Periodic Data: Each quarter, the supplier shall summarize the periodic quality data in a report. This report shall be sent to Peregrine within 2 weeks of the end of the quarter.

  

	8	Records 

  

	 	8.1	Quality Records shall be kept by the supplier for a period of seven years. 

  

	9	Revision History 

  

									
	 DCN#
	  	Revision	  	Date	  	Originator	  	 Description of Change

		  		  		  		  	
		  		  		  		  	
		  		  		  		  	
		  		  		  		  	

  

 B-9 
 *
[***]: Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]